Welcome to our dedicated page for Collegium Pharmaceutical SEC filings (Ticker: COLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Collegium Pharmaceutical, Inc. (Nasdaq: COLL) provides access to the company’s official regulatory submissions as a public biopharmaceutical issuer. These documents, filed with the U.S. Securities and Exchange Commission, offer detailed information on Collegium’s financial condition, risk factors, capital structure, and governance as it advances a portfolio of pain management medications and ADHD-focused neuropsychiatry products.
Investors and analysts can use this page to review periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which describe the company’s business, key products, and risk environment, and present audited or reviewed financial statements. Current reports on Form 8-K, like those cited in recent disclosures, furnish information on material events, including quarterly financial results, earnings presentations, share repurchase authorizations, and other significant corporate actions.
For those examining executive and board matters, proxy statements on Schedule 14A and related filings provide context on governance and compensation policies. Filings related to securities offerings and credit facilities can shed light on how Collegium finances its operations and business development plans, including the use of syndicated credit arrangements and other debt instruments mentioned in company press releases.
In addition, users can monitor beneficial ownership and insider activity through forms such as Form 4, which report transactions in Collegium’s common stock by directors, officers, and certain shareholders. Understanding these filings can help readers interpret how management and insiders interact with COLL shares over time.
On Stock Titan, SEC documents for Collegium are updated as they become available from EDGAR. AI-powered tools can help summarize lengthy filings, highlight key sections on product portfolios, non-GAAP metrics, and risk factors, and make it easier to navigate complex disclosures when researching COLL as an investment or analyzing its regulatory history.
Collegium Pharmaceutical, Inc. (COLL) filed a Form 144 reporting a proposed sale of 4,861 common shares. The shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ with an aggregate market value of $184,880.87. The company reports 31,502,127 shares outstanding, giving context to the size of this proposed sale relative to the total share base.
The filing shows the shares were acquired via an option granted on 02/05/2020 from the issuer and the transaction lists cash as the form of payment. The filer reports no securities sold in the past three months and makes the required representation that they are not aware of material nonpublic information about the issuer.
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation report beneficial ownership of 1,521,170 shares of Collegium Pharmaceutical common stock, representing 4.82% of the class. The filers state they have sole voting and sole dispositive power over these shares and no shared voting or dispositive power. The filing affirms the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. It also notes that certain funds managed by Renaissance have rights to receive dividends and sale proceeds related to these shares. The report identifies one filer as an investment adviser and the other as a holding company.
John G. Freund, a director of Collegium Pharmaceutical, reported sales of common stock with an execution date of 08/08/2025. The filing records a direct sale of 11,659 shares at a weighted-average price of $34.3632, with individual sale prices ranging from $34.27 to $34.535. The Form 4 also includes items showing 70,658 shares marked as disposed and an indirect position of 8,625 shares held through Skyline Venture Management V, LLC. Following the reported transactions the filing identifies 23,129 shares held indirectly by the John Freund Family Partnership IV, L.P. The reporting person disclaims beneficial ownership of shares held by those entities except to the extent of his proportionate pecuniary interest.
The Schedule 13G/A filed for Collegium Pharmaceutical shows Principal Global Investors beneficially owns 1,466,506 shares of Collegium common stock, representing 4.6% of the class. The filing reports shared voting power and shared dispositive power for all 1,466,506 shares and no sole voting or dispositive power. The issuer is identified as Collegium Pharmaceutical (common stock, $0.001 par). The filer certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.